Latest filing published 28 Sept 2026 for Lexeo Therapeutics, Inc., €5,260.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Richard Nolan Townsend on record concern Lexeo Therapeutics, Inc. In total, 38 filings cover trades dated from 5 January 2024 to 14 September 2026.
No open-market purchase appears, only 22 sales worth €1.7M. Besides market trades, the filings include 8 share grants and 8 option exercises. In 2026 alone, the filings show no purchases and 3 sales.
The latest filing, published on 28 September 2026, reports a share grant of €5,260 in Lexeo Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
24 of 24 declarations